Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: Role in drug resistance?

Leukemia Research

Volumn 27, Issue 3, 2003, Pages 267-273

  Hoser, Grazyna ^a   Majsterek, Ireneusz ^b   Romana, Duane L ^c   Slupianek, Artur ^c   Blasiak, Janusz ^b   Skorski, Tomasz ^a,c  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c Temple University   (United States)

Author keywords

BCR ABL; DNA damage; DNA repair; Drug resistance

Indexed keywords

BCR ABL PROTEIN; CYTOSTATIC AGENT; IDARUBICIN; IMATINIB; METHYLNITRONITROSOGUANIDINE; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; GAMMA RADIATION; GENOTOXICITY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TRANSFORMED; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; IDARUBICIN; METHYLNITRONITROSOGUANIDINE; MICE; MUTAGENS; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES;

EID: 0344951307     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00163-7     Document Type: Article

References (46)

1. Kolibaba K.S., Druker B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta. 1333:1997;F217.
2. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature. 411:2001;355.
3. Clark S.S., McLaughlin J., Timmons M., Pendergast A.M., Ben-Neriah Y., Dow L.W.et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 239:1988;775.
4. Epner D.E., Koeffler H.P. Molecular genetic advances in chronic myelogenous leukemia [see comments]. Ann. Int. Med. 113:1990;3.
5. Shtivelman E., Lifshitz B., Gale R.P., Roe B.A., Canaani E. Alternative splicing of RNAs transcribed from the human ABL gene and from the BCR-ABL fused gene. Cell. 47:1986;277.
6. Zou X., Calame K. Signaling pathways activated by oncogenic forms of ABL tyrosine kinase. J. Biol. Chem. 274:1999;18141.
7. Raitano A.B., Whang Y.E., Sawyers C.L. Signal transduction by wild-type and leukemogenic ABL proteins. Biochim. Biophys. Acta. 1333:1997;F201.
8. Sattler M., Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Fact. Rev. 8:1997;63.
9. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9:1994;1829.
10. Masumoto N., Nakano S., Fujishima H., Kohno K., Niho Y. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gall bladder adenocarcinoma cells. Int. J Cancer. 80:1999;731.
11. el-Deiry W.S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 9:1997;79.
12. Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidransky D., Vala M.S.et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 86:1995;1148.
13. Nishii K., Kabarowski J.H., Gibbons D.L., Griffiths S.D., Titley I., Wiedemann L.M.et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene. 13:1996;2225.
14. Amarante-Mendes G.P., Naekyung Kim C., Liu L., Huang Y., Perkins C.L., Green D.R., Bhalla K. BCR-ABL exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 91:1998;1700.
15. Dubrez L., Eymin B., Sordet O., Droin N., Turhan A.G., Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood. 91:1998;2415.
16. Slupianek A., Schmutte C., Tombline G., Nieborowska-Skorska M., Hoser G., Nowicki M.O.et al. Skorski T: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell. 8:2001;795.
17. Slupianek A., Hoser G., Majsterek I., Bronisz A., malecki M., Blasiak J.et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol. Cell Biol. 22:2002;4189.
18. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175:1988;184.
19. Parshad R., Sanford K.K. Radiation-induced chromatid breaks and deficient DNA repair in cancer predisposition. Crit. Rev. Oncol. Hematol. 37:2001;87.
20. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57:1999;727.
21. Autrup H., Stoner G.D. Metabolism of N-nitrosamines by cultured human and rat oesophagus. Cancer Res. 42:1982;1307.
22. Modrich P. Mechanisms and biological effects of mismatch repair. Ann. Rev. Genet. 25:1991;229.
23. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S.et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2:1996;561.
24. Klaude M., Eriksson S., Nygren J., Ahnstrom G. The comet assay: mechanisms and technical considerations. Mutat. Res. 363:1996;89.
25. Rojas E., Lopez M.C., Valverde M. Single cell gel electrophoresis assay: methodology and applications. J. Chromatogr. B Biomed. Sci. Appl. 722:1999;225.
26. Amarante-Mendes G.P., McGahon A.J., Nishioka W.K., Afar D.E., Witte O.N., Green D.R. Bc, l-2-independent BCR-ABL-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene. 16:1998;1383.
27. Johnson B.W., Cepero E., Boise L.H. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. J Biol. Chem. 275:2000;31546.
28. Cambier N., Chopra R., Strasser A., Metcalf D., Elefanty A.G. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 16:1998;335.
29. Gloc E., Warszawski M., Mlynarski W., Stolarska M., Hoser G., Skorski T., Blasiak J. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Acta Biochim. Pol. 49:2002;121-128.
30. Blasiak J., Gloc E., Mlynarski W., Drzewoski J., Skorski T. Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leuk. Res. 26:2002;1093-1096.
31. Majsterek I., Blasiak J., Mlynarski W., Hoser G., Skorski T. Does BCR/ABL-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biol. Int. 26:2002;363.
32. Sillaber C., Gesbert F., Frank D.A., Sattler M., Griffin J.D. STAT5 activation contributes to growth and viability in BCR/ABL-transformed cells. Blood. 95:2000;2118.
33. Moller P., Knudsen L.E., Loft S., Wallin H. The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors. Cancer Epidemiol. Biomarkers Prev. 9:2000;1005.
34. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat. Rev. Cancer. 2:2002;351.
35. Lankinen M.H., Vilpo L.M., Vilpo J.A. UV- and gamma-irradiation-induced DNA single-strand breaks and their repair in human blood granulocytes and lymphocytes. Mutat. Res. 352:1996;31.
36. Wang H., Zeng Z.C., Bui T.A., Sonoda E., Takata M., Takeda S.et al. Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group. Oncogene. 20:2001;2212.
37. DiBiase S.J., Zeng Z.C., Chen R., Hyslop T., Curran W.J. Jr., Iliakis G. DNA-dependent protein kinase stimulates an independently active, non-homologous, end-joining apparatus. Cancer Res. 60:2000;1245.
38. Deutsch E., Dugray A., AbdulKarim B., Marangoni E., Maggiorella L., Vaganay S.et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood. 97:2001;2084.
39. Maru Y., Bergmann E., Coin F., Egly J.M., Shibuya M. TFIIH functions are altered by the P210 BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat. Res. 483:2001;83.
40. Smith G.C., Jackson S.P. The DNA-dependent protein kinase. Genes Dev. 13:1999;916.
41. Zdraveski Z.Z., Mello J.A., Marinus M.G., Essigmann J.M. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 7:2000;39.
42. Kovacic P., Jacintho J.D. Reproductive toxins: pervasive theme of oxidative stress and electron transfer. Curr. Med. Chem. 8:2001;863.
43. Sattler M., Verma S., Shrikhande G., Byrne C.H., Pride Y.B., Winkler T.et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 275:2000;24273.
44. Dierov J., Daley G.Q., Carroll M. BCR-ABL alters the kinetics of DNA repair in transformed cells after DNA double strand damage. Blood. 96:2000;739a.
45. Salloukh H.F., Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia. 14:2000;1401.
46. Canitrot Y., Lautier D., Laurent G., Frechet M., Ahmed A., Turhan A.G.et al. Mutator phenotype of BCR-ABL transfected BaF3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 18:1999;2676.